What Is Integra LifeSciences Holdings C (IART) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Integra LifeSciences Holdings C's intrinsic value is estimated at $21.34, presenting a divided outlook at the current price of $18.58. With an average implied return of +14.9% across a split 5–5 (bull–bear) consensus, the model spread of +281.3% underscores analytical uncertainty. Notably, EPV sees the most upside at +210.1% (fair value: $57.61), while Markov DDM is the most conservative at -71.2% ($5.34). The spread between these extremes — +281.3% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, EPV lean bullish — adding weight to the bullish side of the thesis.
What Do the Models Say About IART?
12 of 13 models are currently active for IART. Of these, 6 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates IART's intrinsic value at $13.21, implying -28.9% downside from the current price. See which stocks rank higher →
How Does IART Rank in Surgical & Medical Instruments & Apparatus?
Among 111 Surgical & Medical Instruments & Apparatus stocks, IART ranks #42 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.
See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →
Integra LifeSciences Holdings C operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is IART a Value Trap?
The Value Trap algorithm is not active for IART. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Integra LifeSciences Holdings C. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Integra LifeSciences Holdings C scores 6.9 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +281.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IART valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IART's 12 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad